Detection of Microorganisms and Antibiotic Resistance Genes Using the Curetis Unyvero LRT55 Application
NCT ID: NCT01922024
Last Updated: 2019-03-05
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2124 participants
OBSERVATIONAL
2015-06-30
2016-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this study, the performance of the Unyvero LRT55 Application shall be tested under clinical conditions and compared to (1) a composite reference method (for non-atypical or cultured microorganisms) or (2) a molecular PCR based reference method for the 3 atypical microorganisms Chlamydophila pneumoniae, Legionella pneumoniae, and Pneumocystis jirovecii, and for resistance genes.
PCR amplifications are followed by bi-directional sequencing, including comparison of the test results Time to result will be compared for the Unyvero LRT55 Application and standard-of care.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Predictive Value of Molecular Diagnostic Techniques in the Antimicrobial- Resistance Phenotypes of Pathogens
NCT07035535
Detection of Pseudomonas Aeruginosa in the Airways of Patients With CF
NCT01303068
Fast Identification of Pathogen in the Setting of Pneumonia Using Multiplex PCR
NCT01858974
Pneumococcal Carriage in Patients With Lower Respiratory Tract Infection (LRTI)
NCT01861184
Prospective Clinical Evaluation of the FilmArray® Lower Respiratory Tract Infection (LRTI) Panel
NCT03361670
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will use leftover lower respiratory tract samples taken from subjects suspected with lower respiratory tract infections: (a) Specimens taken prospectively for standard-of-care (i.e. microbiology testing) from hospitalized subjects. (b) Banked specimens for rare microorganisms.
As the device is under investigation, the test results provided by the Unyvero LRT55 Application will not be made available to the treating physician and therefore will not be used for diagnosis, treatment or other management decisions.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Prospective Fresh Clinical Specimens
Patients with suspicion of lower respiratory tract infection (pneumonia), samples tested with Unyvero LRT 55 cartridge and results compared against composite (comparator) which is based on routine clinical microbiology and a second PCR test
LRT55 Testing
Testing on the Unyvero LRT55
Retrospective Frozen Clinical Specimens
Patients with suspicion of lower respiratory tract infection (pneumonia), samples tested with Unyvero LRT 55 cartridge and results compared against routine clinical microbiology
LRT55 Testing
Testing on the Unyvero LRT55
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LRT55 Testing
Testing on the Unyvero LRT55
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age at least 18 years
* Available surplus respiratory aspirate or bronchial lavage sample
Exclusion Criteria
* Known infection with HIV, HBV or tuberculosis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Global BioClinical
INDUSTRY
Curetis GmbH
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Johannes Bacher
Role: STUDY_DIRECTOR
Curetis GmbH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California Los Angeles (UCLA)
Los Angeles, California, United States
Northwestern Memorial Hospital
Chicago, Illinois, United States
Johns Hopkins Hospital
Baltimore, Maryland, United States
William Beaumont Hospital
Royal Oak, Michigan, United States
Mayo Clinic
Rochester, Minnesota, United States
Columbia Universiy Medical Center / New York-Presbyterian Hosp.
New York, New York, United States
Rochester Medical Center
Rochester, New York, United States
Summa Health System
Akron, Ohio, United States
University of Washington
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CURETIS LRT55 Study - V 6.0
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.